A comparison over 2 decades of disability-free life expectancy at age 65 years for those with long-term conditions in England: Analysis of the 2 longitudinal Cognitive Function and Ageing Studies.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
03 2022
Historique:
received: 22 06 2021
accepted: 03 02 2022
entrez: 15 3 2022
pubmed: 16 3 2022
medline: 7 4 2022
Statut: epublish

Résumé

Previous research has examined the improvements in healthy years if different health conditions are eliminated, but often with cross-sectional data, or for a limited number of conditions. We used longitudinal data to estimate disability-free life expectancy (DFLE) trends for older people with a broad number of health conditions, identify the conditions that would result in the greatest improvement in DFLE, and describe the contribution of the underlying transitions. The Cognitive Function and Ageing Studies (CFAS I and II) are both large population-based studies of those aged 65 years or over in England with identical sampling strategies (CFAS I response 81.7%, N = 7,635; CFAS II response 54.7%, N = 7,762). CFAS I baseline interviews were conducted in 1991 to 1993 and CFAS II baseline interviews in 2008 to 2011, both with 2 years of follow-up. Disability was measured using the modified Townsend activities of daily living scale. Long-term conditions (LTCs-arthritis, cognitive impairment, coronary heart disease (CHD), diabetes, hearing difficulties, peripheral vascular disease (PVD), respiratory difficulties, stroke, and vision impairment) were self-reported. Multistate models estimated life expectancy (LE) and DFLE, stratified by sex and study and adjusted for age. DFLE was estimated from the transitions between disability-free and disability states at the baseline and 2-year follow-up interviews, and LE was estimated from mortality transitions up to 4.5 years after baseline. In CFAS I, 60.8% were women and average age was 75.6 years; in CFAS II, 56.1% were women and average age was 76.4 years. Cognitive impairment was the only LTC whose prevalence decreased over time (odds ratio: 0.6, 95% confidence interval (CI): 0.5 to 0.6, p < 0.001), and where the percentage of remaining years at age 65 years spent disability-free decreased for men (difference CFAS II-CFAS I: -3.6%, 95% CI: -8.2 to 1.0, p = 0.12) and women (difference CFAS II-CFAS I: -3.9%, 95% CI: -7.6 to 0.0, p = 0.04) with the LTC. For men and women with any other LTC, DFLE improved or remained similar. For women with CHD, years with disability decreased (-0.8 years, 95% CI: -3.1 to 1.6, p = 0.50) and DFLE increased (2.7 years, 95% CI: 0.7 to 4.7, p = 0.008), stemming from a reduction in the risk of incident disability (relative risk ratio: 0.6, 95% CI: 0.4 to 0.8, p = 0.004). The main limitations of the study were the self-report of health conditions and the response rate. However, inverse probability weights for baseline nonresponse and longitudinal attrition were used to ensure population representativeness. In this study, we observed improvements to DFLE between 1991 and 2011 despite the presence of most health conditions we considered. Attention needs to be paid to support and care for people with cognitive impairment who had different outcomes to those with physical health conditions.

Sections du résumé

BACKGROUND
Previous research has examined the improvements in healthy years if different health conditions are eliminated, but often with cross-sectional data, or for a limited number of conditions. We used longitudinal data to estimate disability-free life expectancy (DFLE) trends for older people with a broad number of health conditions, identify the conditions that would result in the greatest improvement in DFLE, and describe the contribution of the underlying transitions.
METHODS AND FINDINGS
The Cognitive Function and Ageing Studies (CFAS I and II) are both large population-based studies of those aged 65 years or over in England with identical sampling strategies (CFAS I response 81.7%, N = 7,635; CFAS II response 54.7%, N = 7,762). CFAS I baseline interviews were conducted in 1991 to 1993 and CFAS II baseline interviews in 2008 to 2011, both with 2 years of follow-up. Disability was measured using the modified Townsend activities of daily living scale. Long-term conditions (LTCs-arthritis, cognitive impairment, coronary heart disease (CHD), diabetes, hearing difficulties, peripheral vascular disease (PVD), respiratory difficulties, stroke, and vision impairment) were self-reported. Multistate models estimated life expectancy (LE) and DFLE, stratified by sex and study and adjusted for age. DFLE was estimated from the transitions between disability-free and disability states at the baseline and 2-year follow-up interviews, and LE was estimated from mortality transitions up to 4.5 years after baseline. In CFAS I, 60.8% were women and average age was 75.6 years; in CFAS II, 56.1% were women and average age was 76.4 years. Cognitive impairment was the only LTC whose prevalence decreased over time (odds ratio: 0.6, 95% confidence interval (CI): 0.5 to 0.6, p < 0.001), and where the percentage of remaining years at age 65 years spent disability-free decreased for men (difference CFAS II-CFAS I: -3.6%, 95% CI: -8.2 to 1.0, p = 0.12) and women (difference CFAS II-CFAS I: -3.9%, 95% CI: -7.6 to 0.0, p = 0.04) with the LTC. For men and women with any other LTC, DFLE improved or remained similar. For women with CHD, years with disability decreased (-0.8 years, 95% CI: -3.1 to 1.6, p = 0.50) and DFLE increased (2.7 years, 95% CI: 0.7 to 4.7, p = 0.008), stemming from a reduction in the risk of incident disability (relative risk ratio: 0.6, 95% CI: 0.4 to 0.8, p = 0.004). The main limitations of the study were the self-report of health conditions and the response rate. However, inverse probability weights for baseline nonresponse and longitudinal attrition were used to ensure population representativeness.
CONCLUSIONS
In this study, we observed improvements to DFLE between 1991 and 2011 despite the presence of most health conditions we considered. Attention needs to be paid to support and care for people with cognitive impairment who had different outcomes to those with physical health conditions.

Identifiants

pubmed: 35290368
doi: 10.1371/journal.pmed.1003936
pii: PMEDICINE-D-21-02730
pmc: PMC8923437
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003936

Subventions

Organisme : Medical Research Council
ID : G0601022
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9901400
Pays : United Kingdom
Organisme : The Dunhill Medical Trust
ID : RPGF1806/44
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: CB is an Academic Editor on PLOS Medicine’s editorial board. FM is a paid statistical consultant on PLOS Medicine’s statistical board.

Références

EClinicalMedicine. 2021 Jul 31;39:101041
pubmed: 34386756
PLoS One. 2019 Jul 3;14(7):e0218991
pubmed: 31269039
Neurology. 2020 Aug 4;95(5):e519-e531
pubmed: 32611641
PLoS One. 2016 Aug 02;11(8):e0160264
pubmed: 27482903
Lancet Diabetes Endocrinol. 2016 Aug;4(8):686-694
pubmed: 27298181
Disabil Rehabil. 2009;31(9):701-11
pubmed: 18979275
Obesity (Silver Spring). 2009 Feb;17(2):363-9
pubmed: 19023280
BMC Geriatr. 2019 Jan 18;19(1):16
pubmed: 30658578
Brain Sci. 2021 Feb 10;11(2):
pubmed: 33578677
PLoS One. 2016 Sep 02;11(9):e0161705
pubmed: 27589586
J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):408-14
pubmed: 17452735
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Alzheimers Dis. 2018;66(2):653-680
pubmed: 30347617
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
BMC Public Health. 2021 Jun 29;21(1):1268
pubmed: 34187450
Lancet Neurol. 2016 Jan;15(1):116-24
pubmed: 26300044
J Gerontol A Biol Sci Med Sci. 2005 Feb;60(2):248-54
pubmed: 15814870
Heart. 2016 Dec 15;102(24):1945-1952
pubmed: 27550425
Stroke Res Treat. 2012;2012:436125
pubmed: 22550614
Nat Rev Neurol. 2017 Jun;13(6):327-339
pubmed: 28497805
J Aging Health. 2011 Apr;23(3):554-77
pubmed: 21139078
PLoS Med. 2020 Oct 9;17(10):e1003366
pubmed: 33035232
J Women Aging. 2002;14(1-2):61-83
pubmed: 12537280
Stroke. 2013 Jul;44(7):2064-89
pubmed: 23652265
Lancet. 2017 Oct 7;390(10103):1676-1684
pubmed: 28821408
BMJ Open. 2020 Sep 21;10(9):e040348
pubmed: 32958494
Age Ageing. 2015 Sep;44(5):867-73
pubmed: 26276156
Disabil Rehabil. 2016;38(4):354-61
pubmed: 25936731
BMJ Open. 2021 May 25;11(5):e045567
pubmed: 34035101
Age Ageing. 2020 Feb 27;49(2):264-269
pubmed: 31808792
Int J Epidemiol. 2021 Jul 9;50(3):841-851
pubmed: 33421052
J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(Suppl_1):S21-S26
pubmed: 31724057
J Gerontol B Psychol Sci Soc Sci. 2020 Aug 13;75(7):e151-e160
pubmed: 31059564

Auteurs

Holly Q Bennett (HQ)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.

Andrew Kingston (A)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.

Ilianna Lourida (I)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.

Louise Robinson (L)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.

Lynne Corner (L)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.

Carol Brayne (C)

Cambridge Public Health, University of Cambridge, Cambridge, United Kingdom.

Fiona E Matthews (FE)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.

Carol Jagger (C)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH